Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | VEGFA | P15692 | 3/20 | 0.51 |
| ▸ | FLT1 | P17948 | 3/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.51 |
| ▸ | TET3 | O43151 | 1/20 | 0.51 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.51 |
| ▸ | ASPH | Q12797 | 1/20 | 0.51 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.51 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.51 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.51 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.51 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319645 | 0.83 | ESR2 (0.54) | ESR2VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL23501739 | 0.83 | ALOX5 (0.59) | ALOX5ESR2VEGFAFLT1EGLN1 | |
| SCHEMBL17946110 | 0.81 | EGLN1 (0.50) | ESR2EGLN1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL10647000 | 0.80 | KDM4E (0.51) | ALOX5VEGFAFLT1EGLN1EGLN3 | |
| SCHEMBL14157215 | 0.80 | FYN (0.59) | ALOX5ESR2VEGFAFLT1EGLN1 | |
| SCHEMBL23501760 | 0.80 | ALOX5 (0.56) | ALOX5ESR2VEGFAFLT1EGLN1 | |
| SCHEMBL19393710 | 0.78 | EGLN1 (0.63) | ALOX5ESR2VEGFAFLT1EGLN1 | |
| SCHEMBL22239416 | 0.78 | FYN (0.56) | VEGFAFLT1EGLN1EGLN3SMN1; SMN2 | |
| SCHEMBL2616121 | 0.77 | SMN1; SMN2 (0.54) | ALOX5ESR2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11467969 | 0.77 | ALOX5 (0.55) | ALOX5ESR2VEGFAFLT1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AKEBIA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3683209-B1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | AKEBIA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| WO-2021117767-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | 田辺三菱製薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021087144-A1 | THERAPEUTIC METHODS USING VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AASDHPPT, AADAT, ALDH7A1 | ALOX5 642/4885ESR2 4596/4885VEGFA 2569/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | ALOX5 988/4885ESR2 4721/4885VEGFA 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.